Brief: Ascletis Announces U.S. IND Approval Of Oral Pd-L1 Small Molecule Inhibitor Asc61 For Treatment Of Advanced Solid Tumors
06/02/2022 10:35
Feb 6 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES U.S. IND APPROVAL OF ORAL PD-L1 SMALL
MOLECULE INHIBITOR ASC61 FOR TREATMENT OF ADVANCED SOLID TUMORS
* THE FIRST U.S. PATIENT IS EXPECTED TO BE DOSED IN THE
FIRST HALF
OF 2022
* ASC61 SHOWS SIGNIFICANT ANTITUMOR EFFICACY AS A SINGLE
AGENT IN
VARIOUS ANIMAL MODELS
Source text for Eikon: ID:nPn9GNHPma
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management